drugset / Trial / NCT01265615

Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

NCT01265615

RandomizedParallel-groupDouble-blindTreatment

Summary

We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac syndrome (CRS). We assume that paricalcitol can have some advantages if compare with calcitriol or cholecalciferol due to absence of calcemic and phosphatemic complications alongside with great beneficial potential.

Timeline

Start
2009-10
Primary completion
2010-04
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcitriol Small molecule 2 ug Oral
Comparator Calcitriol Small molecule 4 ug Oral
Comparator Cholecalciferol Other / unclassified 1200 iu
Comparator Cholecalciferol Other / unclassified 2400 iu
Comparator Paricalcitol Other / unclassified 6 ug Oral
Comparator Paricalcitol Other / unclassified 8 ug Oral